Adam Torres and Gina Fioretti discuss personalized lifecare.

Subscribe: iTunes / Spotify / Stitcher / RSS

Apply to be a guest on our podcast here

Show Notes:

Healthcare changes in the future to become personalized lifecare is an exciting concept. In this episode,  Adam Torres and Gina Fioretti, Founder & Epigeneticist at mylifeIQ, explore the future of personalized lifecare.

About Gina Fioretti

Scientist, entrepreneur, speaker and innovator of consumer genomic testing. Developed the first gender-specific weight loss program based on one’s DNA. Has been an educator to health care practitioners and Fortune 500 companies on the paradigm shift of optimized genetic expression and longevity.

mylifeIQ is a culmination of my many years of learning, failing, succeeding, and connecting dots. For over 12 years, She has been developing practical solutions for individuals that are accessible and actionable. mylifeIQ’s core values; simplicity, accessibility and efficiency. They give people information about their bodies that is too hard to access and too confusing to use. By merging epigenetics and technology, they can begin to upregulate ‘good’ variations, downregulate ‘bad’ variations, consider all the other contributing factors, and allow the body to run efficiently rather than a deficit. And quality of life improves. 

Apply to be a guest on our podcast here

Learn our podcasting system in under 1hr FREE here

Get the Mission Matters News FREE here

Share.
Adam Torres

Adam Torres is Host of the Mission Matters series of shows, ranked in the top 5% out of 3,268,702 podcasts globally. As Co-Founder of Mission Matters, a media, PR, marketing and book publishing agency, Adam is dedicated to amplifying the voices of entrepreneurs, entertainers, executives and experts. An international speaker and author of multiple books on business and investing, his advice is featured regularly in major media outlets such as Forbes, Yahoo! Finance, Fox Business, and CBS to name a few.

Please ensure Javascript is enabled for purposes of website accessibility
×

Thank You for Subscribing.